Dr Ilva Dana Rupenthal
PhD, BPharm, DipLang
Dr Rupenthal is currently a Senior Lecturer in the Department of Ophthalmology and the Director of the Buchanan Ocular Therapeutics Unit, which aims to develop and translate ocular therapeutic related scientific research into the clinical setting. Ilva received a BPharm from the Philipps-University of Marburg, Germany, in 2003 and completed a PhD on ‘Ocular delivery of antisense oligonucleotides’ with the School of Pharmacy and the Department of Ophthalmology, University of Auckland, in 2008. In 2010, Ilva was awarded a prestigious three-year New Zealand Science and Technology Postdoctoral Fellowship to establish an ocular pharmaceutics group within the New Zealand National Eye Centre. In 2013, she then received a prestigious $500,000 HRC Sir Charles Hercus Research Fellowship to continue her innovative research into stimuli-responsive ocular implants. Dr Rupenthal has received several awards including the 2016 HRC Celebrating Research Excellence Award and the 2014 University of Auckland Early Career Research Excellence Award, while also being a winner of the Spark Entrepreneurship Ideas Challenges in 2012 and 2014.
Research | Current
The Buchanan Ocular Therapeutics Unit (BOTU) aims to develop and translate ocular therapeutic related scientific research into the clinical setting whether pharmaceutical-, cell- or technology-based. Current research focusses on the development of stimuli-responsive ocular implants that are able to slowly release the drug over time, while also allowing for non-invasive top-up dosing based on individual patient needs. Moreover, her group is evaluating novel drug therapies for the treatment of sight-threatening diseases such as age-related macular degeneration and diabetic retinopathy.
For further information on current research of the Unit, please visit the BOTU website (link on the right).
Dr Rupenthal supervises postgraduate students at Masters and PhD level in the area of stimuli-responsive ocular implants and novel treatments for ocular dieases.
For more information on student supervision and projects available, please visit the BOTU website (link on the right).
- Health Research Council Celebrating Research Excellence Award (2016)
- Senior Scholar Award in the Faculty of Arts, University of Auckland (2015)
- Early Career Research Excellence Award, University of Auckland (2014)
- Spark Entrepreneurship Ideas Challenge Prize (2014)
- Health Research Council Sir Charles Hercus Health Research Fellowship (2013)
- Spark Entrepreneurship Ideas Challenge UniServices Prize (2012)
- Foundation of Research, Science and Technology Postdoctoral Fellowship (2010)
- New Zealand Postgraduate Study Abroad Award (2006)
- Harriette Jenkins Award, New Zealand Federation of Graduate Women (2006)
- University of Auckland International Doctoral Scholarship (2005)
- Young Microscopist Award, Otago University (2005)
- Director of the Buchanan Ocular Therapeutics Unit
- FMHS Equity Committee Member
- Department of Ophthalmology Graduate Advisor
Areas of expertise
Ocular drug delivery
Selected publications and creative works (Research Outputs)
- Ramtin, A., Seyfoddin, A., Coutinho, F. P., Waterhouse, G. I. N., Rupenthal, I. D., & Svirskis, D. (2016). Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions. Drug Delivery and Translational Research, 6 (6), 793-799. 10.1007/s13346-016-0284-0
Other University of Auckland co-authors: Geoffrey Waterhouse, Darren Svirskis, Frazer Coutinho
- Agarwal, P., & Rupenthal, I. D. (2016). In vitro and ex vivo corneal penetration and absorption models. Drug delivery and translational research, 6 (6), 634-647. 10.1007/s13346-015-0275-6
- Agarwal, P., & Rupenthal, I. D. (2016). Modern approaches to the ocular delivery of cyclosporine A. Drug discovery today, 21 (6), 977-988. 10.1016/j.drudis.2016.04.002
- Agban, Y., Lian, J., Prabakar, S., Seyfoddin, A., & Rupenthal, I. D. (2016). Nanoparticle cross-linked collagen shields for sustained delivery of pilocarpine hydrochloride. International Journal of Pharmaceutics, 501 (1-2), 96-101. 10.1016/j.ijpharm.2016.01.069
Other University of Auckland co-authors: Yosra Agban
- Danesh-Meyer, H. V., Zhang, J., Acosta, M. L., Rupenthal, I. D., & Green, C. R. (2016). Connexin43 in retinal injury and disease. Progress in Retinal and Eye Research, 51, 41-68. 10.1016/j.preteyeres.2015.09.004
Other University of Auckland co-authors: Helen Danesh-Meyer, Colin Green, Jie Zhang, Monica Acosta
- Bisht, R., Jaiswal, J. K., Chen, Y. S., Jin, J., & Rupenthal, I. D. (2016). Light-responsive in situ forming injectable implants for effective drug delivery to the posterior segment of the eye. Expert Opinion on Drug Delivery, 13 (7), 953-962. 10.1517/17425247.2016.1163334
Other University of Auckland co-authors: Jianyong Jin, Jagdish Jaiswal
- Chen, Y.-S., Green, C. R., Teague, R., Perrett, J., Danesh-Meyer, H. V., Toth, I., & Rupenthal, I. D. (2015). Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia. Drug Delivery and Translational Research, 5 (5), 480-488. 10.1007/s13346-015-0249-8
Other University of Auckland co-authors: Colin Green, Helen Danesh-Meyer
- Chen, Y.-S., Green, C. R., Danesh-Meyer, H. V., & Rupenthal, I. D. (2015). Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 95 (Pt B), 182-193. 10.1016/j.ejpb.2015.01.031
Other University of Auckland co-authors: Helen Danesh-Meyer, Colin Green